This website uses cookies. By continuing to browse this website you are agreeing to our use of cookies. Find out more by reading our privacy policy. Read more
Stay up to date on current diabetes themes, proved therapeutic options, and knowledge resources and tools for you and your patients & find detailed information on Novo Nordisk diabetes products: Tresiba® (insulin degludec), Victoza® (liraglutide injection), Levemir® (insulin detemir), NovoMix® (biphasic insulin aspart), NovoRapid® (insulin aspart), and our pens & devices.
Novo Nordisk provides localized information to HCPs in the following countries:
According to applicable law, only Health Care Professionals are allowed to access the product information in this section.
Information for patients and relatives
Haemostasis management
NovoSeven®
Dosing
Storage information
Vial information
Management
Blood coagulation
Key papers
Treatment guidelines
Services & links
WFH patients' leaflet
Patient story
Congenital haemophilia
Acquired haemophilia
Factor VII deficiency
Glanzmann's thrombasthenia
According to applicable law, only Health Care Professionals are allowed to access the product information in this section.
Information for patients and relatives
Growth hormone therapy overview
Norditropin®
GHD (Growth hormone deficiency)
GHDA (Growth hormone deficiency) in adults
SGA (Small for gestational age)
Turner syndrome
Noonan syndrome
Skeletal dysplasia
Chronic renal disease
Prader-Willi syndrome
Norditropin® FlexPro®
Norditropin NordiFlex®
NordiPen® with Norditropin® SimpleXx®
Norditropin® NordiLet®
NovoFine®
NordiNet® (outcomes registry)
NordiScience® (HCP support)
NordiCare® (Patient support)
Our partnership with Save the Children
Testimonials
According to applicable law, only Health Care Professionals are allowed to access the product information in this section.
Information for patients and relatives
Overview
Introduction
Activelle®
Eviana®
Novofem®
Estrofem®
Vagifem®
Convenience & compliance
Our history in HRT
Introduction
Symptoms & complaints
Duration of treatment
Oestrogen
Progestogen
Continuous combined HRT
Sequential combined HRT
Low-dose HRT
According to applicable law, only Health Care Professionals are allowed to access the product information in this section.
Information for patients and relatives
Stay up to date on current diabetes themes, proved therapeutic options, and knowledge resources and tools for you and your patients & find detailed information on Novo Nordisk diabetes products: Tresiba® (insulin degludec), Victoza® (liraglutide injection), Levemir® (insulin detemir), NovoMix® (biphasic insulin aspart), NovoRapid® (insulin aspart), and our pens & devices.
Novo Nordisk provides localized information to HCPs in the following countries:
According to applicable law, only Health Care Professionals are allowed to access the product information in this section.
Information for patients and relatives
According to applicable law, only Health Care Professionals are allowed to access the product information in this section.
Information for patients and relatives
According to applicable law, only Health Care Professionals are allowed to access the product information in this section.
Information for patients and relatives
According to applicable law, only Health Care Professionals are allowed to access the product information in this section.
Information for patients and relatives
Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs approximately 35,500 employees in 75 countries, and markets its products in more than 180 countries.
Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
APROM ID# 3950. May 2012.
Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs approximately 34,700 employees in 75 countries, and markets its products in 180 countries.
| NovoMedLink |
Novo Nordisk in the USA |
Novo Nordisk in Denmark |
Or choose:
